January 4, 2018 / 5:44 PM / 2 months ago

BRIEF-Catalyst Biosciences Initiates Phase 2/3 Trial Of Marzeptacog Alfa (Activated)

Jan 4 (Reuters) - Catalyst Biosciences Inc:

* CATALYST BIOSCIENCES INITIATES PHASE 2/3 TRIAL OF MARZEPTACOG ALFA (ACTIVATED) FOR PROPHYLAXIS IN HEMOPHILIA A OR B WITH INHIBITORS

* CATALYST BIOSCIENCES INC - ‍INTERIM DATA FOR PHASE 2 MARZAA TRIAL​ EXPECTED TO BE ANNOUNCED IN FIRST HALF OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below